Aripiprazole
产品说明书
 |
同义名 : | OPC-14597; OPC 31 |
| CAS号 : | 129722-12-9 | |
| 货号 : | A134405 | |
| 分子式 : | C23H27Cl2N3O2 | |
| 纯度 : | 98% | |
| 分子量 : | 448.39 | |
| MDL号 : | MFCD00892072 | |
| 存储条件： |
Pure form Sealed in dry, room temperature In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Aripiprazole, a partial agonist at dopamine D2 receptors, mainly used as a kind of antipsychotic[3]. In vitro studies, aripiprazole could inhibite the growth of serum-cultured cancer cells and cancer stem cells, induce differentiation and suppress sphere formation while had non-toxic to normal cells[4]. In vivo studies, it was found that long-term administration of aripiprazole could restore DARPP-32 phosphorylation changes in response to sucrose and reinstate the motivational drive to acquire the reward in the progressive ratio task in non food-deprived 9-week old male Sprague-Dawley rats, while wouldn’t restore reactivity to aversive stimuli[5]. Besides this, after administration for 28 days in rats, aripiprazole contributed to the decreases of D2 receptor levels in various regions and 5-HT2A receptors in the MPC, DFC, HIPP-CA1, and HIPP-CA3 regions, as well as the increasing of 5-HT1A receptors in the MPC and DFC, and 5-HT1A receptors in HIPP-CA1 and HIPP-CA3[6]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01739127 | - | Completed | - | Canada, British Columbia ... 展开 >> BC Mental Health & Addictions Research Institute Vancouver, British Columbia, Canada, V5Z 4H4 收起 << | |
| NCT00806234 | Psychotic Disorders | Phase 4 | Completed | - | United States, Maryland ... 展开 >> University of Maryland Baltimore, Maryland, United States, 21201 Johns Hopkins Hospital Baltimore, Maryland, United States, 21205 United States, New York The Zucker Hillside Hospital Glen Oaks, New York, United States, 11004 United States, North Carolina University of North Carolina, Division of Child and Adolescent Psychiatry Chapel Hill, North Carolina, United States, 27599 收起 << |
| NCT00895921 | Diabetes | Phase 4 | Completed | - | United States, California ... 展开 >> VA San Diego Healthcare System San Diego, California, United States, 92161 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.23mL 0.45mL 0.22mL |
11.15mL 2.23mL 1.12mL |
22.30mL 4.46mL 2.23mL |
| 参考文献 |
|---|